Proof-of-principle concept for label-free detection of glucose and alpha-glucosidase activity

Research offers hope of better diagnosis and treatment for Pompe disease patients

Glycogen storage disease type II (GSD II), also known as Pompe disease, is a genetic disorder that results in muscle and nerve cell damage caused by deficiency of the lysosomal acid a-glucosidase enzyme. In an effort to achieve a better technique for screening enzyme activity in patients suffering from Pompe disease, Prof. Vivian Yam and colleagues at the Institute of Molecular Functional Materials, University of Hong Kong, have synthesised a two-component platinum (II) complex-polymer ensemble for glucose sensing and a-glucosidase assay.

The system works by strongly binding glucose, resulting in a 46-fold increase in the low energy emission band (800 nm) of the electronic emission spectrum. Additionally, in the presence of a-glucosidase and maltose (which is broken down to glucose by a-glucosidase), the intensity of the 800 nm emission band was found to increase with time. These results provide a “proof-of-principle” concept for label-free detection of glucose and open the way for rapid and sensitive detection of a-glucosidase.

To find out more download the ChemComm communication for free until 25th February 2011.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)